Social Media Ideas for Biopharma

For biopharma manufacturing at speed and scale, the future is flexible

Biopharma development has long trended toward specialized and personalized therapies such as cell and gene therapies, antibody-drug conjugates, and monoclonal antibodies (mAbs), am...

<![CDATA[Additive Manufacturing's Application in Pharma and Biotech]]>

<![CDATA[How Regulatory Stringency, Demand Shocks, and Repurposing Reshape Biopharma Strategy in 2026]]>

<![CDATA[The Evolving Relationship Between FDA and Biotech]]>

Puerto Rico makes its case as a biotech manufacturing hub

Puerto Rico is building on its pharma manufacturing legacy to attract advanced therapy developers seeking scale, regulatory alignment and speed.

<![CDATA[Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpha...

<![CDATA[Pharma M&A Roundup: Protillion Biosciences Enters Drug Discovery Collaboration with Merck, Jazz Pharmace...

From Discovery to Development in Emerging Modalities

ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities a...

Managing complexity across biopharma modalities

SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.

Biopharma moves to reduce development risk earlier than ever

Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.

Major Biopharmaceutical Company Files First-in-Human Trial Supported by PAK BioSolutions GMP Purification System

A major biopharmaceutical company has filed a First-in-Human (FIH) clinical trial application with drug product manufactured using the PAK BioSolutions system. The milestone demons...

Taiwan's biopharma sector steps into spotlight with rush of IPOs

A New Approach to Supporting Quality of Biologics

The United States Pharmacopeia (USP) is proposing a new approach for its work to support the quality and availability of selected biologic medicines. Building on decades of experie...

<![CDATA[Nuvation Bio’s Global Strategy]]>

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Pharma at a Political Crossroads]]>

<![CDATA[The Industry's Interest in Vaccine Platforms]]>

'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared tha...

<![CDATA[Targeted Onshoring's Impact on Domestic Pharma Manufacturing]]>

<![CDATA[Parabilis Medicines Raises $670 Million in Initial Public Offering ]]>

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

<![CDATA[What’s Next in Access & Affordability: A Biopharma Perspective]]>

Next Generation Biopharma Innovation

In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies. The post Next Generation Biopharma Innovation appear...